logo

AARTIDRUGS vs INDOCO: Stock Comparison

AARTI DRUGS vs INDOCO REMEDIESUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

AARTI DRUGS is the larger company by market capitalisation. AARTI DRUGS shows a lower P/E, a higher ROE and a higher dividend yield, while INDOCO REMEDIES shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

AARTIDRUGS leads 8; INDOCO leads 3 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

AARTIDRUGSINDOCO

Valuation lens

What price are you paying?

Market CapContext only
₹3,478 Cr
₹2,077 Cr
P/E RatioAARTIDRUGS has the lower reading
18.19x ✓
368.85x
P/B RatioINDOCO has the lower reading
2.25x
2.21x ✓
EPSAARTIDRUGS has the higher reading
₹20.93 ✓
₹7.04
Book ValueContext only
₹169.79
₹100.98
Dividend YieldAARTIDRUGS has the higher reading
0.5% ✓
0.09%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
AARTIDRUGS is the larger company
₹3,478 Cr vs ₹2,077 Cr
P/E Ratio
AARTIDRUGS has a lower P/E
18.19x vs 368.85x
P/B Ratio
INDOCO has a lower P/B
2.21x vs 2.25x
EPS
AARTIDRUGS has higher earnings per share
₹20.93 vs ₹7.04
Dividend Yield
AARTIDRUGS has a higher dividend yield
0.5% vs 0.09%
Revenue Growth (TTM YoY)
INDOCO has faster revenue growth
21.9% vs 6.4%
EPS Growth (TTM YoY)
INDOCO has faster EPS growth
0% vs -12%
ROE
AARTIDRUGS has a higher ROE
12.05% vs -0.51%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIDRUGSINDOCO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIDRUGSINDOCO
Live Price₹380.05₹225.6
Day Change-2.2%-2.55%
Volume1.59 L1.07 L
52-Week High₹534₹291
52-Week Low₹318.95₹162.19
Distance from 52W High-28.83%-22.47%

Valuation

MetricAARTIDRUGSINDOCO
Market Cap₹3,478 Cr₹2,077 Cr
P/E Ratio18.19x368.85x
P/B Ratio2.25x2.21x
EPS₹20.93₹7.04
Book Value₹169.79₹100.98
Dividend Yield0.5%0.09%

Growth

MetricAARTIDRUGSINDOCO
Revenue Growth (TTM YoY)6.4%21.9%
EPS Growth (TTM YoY)-12%0%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricAARTIDRUGSINDOCO
ROE12.05%-0.51%
ROCE10.64%4.26%
Net Margin7.6%-5.31%
Operating Margin9.19%4.57%
Debt to Equity0.3x0.64x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricAARTIDRUGSINDOCO
Promoter Holding54.07%▼ 0.36 pp58.86%
FII Holding2.26%▲ 0.74 pp1.27%▲ 0.33 pp
DII Holding10.24%▼ 0.05 pp17.68%▼ 0.47 pp
Public Holding33.43%▼ 0.32 pp22.04%▲ 0.14 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AARTI DRUGS and INDOCO REMEDIES.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.